Zobrazeno 1 - 10
of 364
pro vyhledávání: ''
Autor:
Bruce A. Littlefield, Elodie Modave, Amy Weaver, Bram Boeckx, Diether Lambrechts, Agnieszka Wozniak, Patrick Schöffski
Publikováno v:
Clinical Cancer Research. 27:3106-3115
Purpose:A randomized phase III study evaluated the efficacy of eribulin versus dacarbazine in patients with advanced liposarcoma and leiomyosarcoma. Improved overall survival (OS) led to approval of eribulin for liposarcoma, but not for leiomyosarcom
Autor:
Satoshi Yoda, Wafa Malik, Adam Langenbucher, Justin F. Gainor, Sai-Hong Ignatius Ou, Kylie Prutisto-Chang, Ramin Sakhtemani, Jennifer L Peterson, Aaron N. Hata, Alexander Drilon, Andrew Do, Jessica J. Lin, Adam J. Schoenfeld, Viola W. Zhu, Ted William Johnson, Jochen K. Lennerz, Lecia V. Sequist, Noura J. Choudhury, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Christina Falcon, Charlotte E. Lee, Alice T. Shaw, Michael S. Lawrence, Beow Y. Yeap, Jennifer S. Temel, Harper Hubbeling
Publikováno v:
Clin Cancer Res
Purpose: Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is crizotinib or entrectinib. Lorlatinib, a next-generation anaplastic lymphoma
Autor:
Eva Ciruelos, Ingrid A. Mayer, Chong Ma, Sibylle Loibl, Dejan Juric, Albert Reising, Hope S. Rugo, Michelle Miller, Hiroji Iwata, Mario Campone, Pierfranco Conte, Fabrice Andre, Naveen Babbar, Monica Arnedos
Publikováno v:
Cancer Research. 81:PD2-06
Introduction: The PI3K pathway is often hyperactivated in cancer as a result of an altered PI3K isoform and/or loss of phosphatase and tensin homolog function. Approximately 40% of patients (pts) with hormone receptor-positive (HR+), human epidermal
Autor:
Brenda J. Weigel, Keith D. Wilner, David Hall, Charles G. Minard, Jennifer Foster, Peter C. Adamson, Stacey L. Berg, Elizabeth Fox, Susan M. Blaney, Stephan D. Voss, Yael P. Mosse, Frank M. Balis
Publikováno v:
Clinical Cancer Research. 27:3543-3548
Purpose: Anaplastic lymphoma kinase (ALK) aberrations are a promising target for patients with neuroblastoma. We assessed the activity of first-generation ALK inhibitor crizotinib in patients with no known curative treatments and whose tumors harbore
Autor:
Salvatore Siena, Daniel Moya-Rull, Andrea Sartore-Bianchi, Emanuele Rausa, Annalisa Petrelli, Annunziata Gloghini, Brian M. Alexander, Daniela Conticelli, Asa Dahle-Smith, Sara Erika Bellomo, Filippo Pietrantonio, J. Lee, Siraj M. Ali, Giovanni Sgroi, Vincent A. Miller, Federica Morano, Salvatore Corallo, Uberto Fumagalli, Silvia Giordano, Maria Di Bartolomeo, Caterina Marchiò, Giovanni de Manzoni, Anna Sapino, Antonino Sottile, Stefano De Pascale, Gian Luca Baiocchi, Laura D'Errico, Silvia Marsoni, Rossella Reddavid, Simona Corso, Michele Prisciandaro, Stefania Durando, Zosia Miedzybrodzka, Cristina Migliore, Alexa B. Schrock, Russell D. Petty, Maria Apicella, Jeffrey S. Ross, Maurizio Degiuli, Sarah Molfino, Maria Bencivenga, Stefano Ughetto
Publikováno v:
Clinical Cancer Research. 27:3126-3140
Purpose: Gastric and gastroesophageal adenocarcinomas represent the third leading cause of cancer mortality worldwide. Despite significant therapeutic improvement, the outcome of patients with advanced gastroesophageal adenocarcinoma is poor. Randomi
Autor:
Dongsheng Tu, Timothy J. Price, Hagen F. Kennecke, Daniel L. Edelstein, Scott Kopetz, Frank Holtrup, Hannah Quinn, Anthony Dowers, Stanley R. Hamilton, Derek J. Jonker, John Zalcberg, Christos S Karapetis, Paul Waring, Jonathan M. Loree, Christopher J. O'Callaghan, Malcolm J. Moore
Publikováno v:
Clinical Cancer Research. 27:52-59
Purpose: Expanded RAS/BRAF mutations have not been assessed as predictive for single-agent cetuximab in metastatic colorectal cancer (mCRC), and low mutant allele frequency (MAF) mutations are of unclear significance. We aimed to establish cetuximab
Autor:
Jan H. Beumer, Huichen Feng, Ashwin Reddy Sama, Thomas J. George, Corey Lipchik, Carmen J. Allegra, Melanie Finnigan, Philip J. Stella, James L. Wade, Katherine L. Pogue-Geile, Ying Wang, Patrick G. Gavin, Ashok Srinivasan, James J. Lee, Rim S. Kim, Norman Wolmark, Brian F. Kiesel, Peter C. Lucas, Fanny Piette, Samuel A. Jacobs, Ding Wang
Publikováno v:
Clinical Cancer Research. 27:1612-1622
Purpose: In metastatic colorectal cancer (mCRC), HER2 (ERBB2) gene amplification is implicated in anti-EGFR therapy resistance. We sought to determine the recommended phase II dose (RP2D) and efficacy of neratinib, a pan-ERBB kinase inhibitor, combin
Autor:
Richard Price, Christine Ju, Johanna C. Bendell, Herbert Hurwitz, Xiaoju Max Ma, John Lee, Nalin Tikoo, Christoph Mancao, Lijing Yao, Alex Lovejoy, Alan Nicholas, Stephanie J. Yaung, John F. Palma, Nicolas Sommer
Publikováno v:
Clinical Cancer Research. 26:4010-4017
Purpose:We assessed plasma circulating tumor DNA (ctDNA) level as a prognostic marker for progression-free survival (PFS) following first-line metastatic colorectal cancer (mCRC) therapy.Experimental Design:The Sequencing Triplet With Avastin and Mai
Autor:
Philipp Lohneis, Jana Käthe Striefler, Hendrik Bläker, Uwe Pelzer, Marcus Bahra, Carsten Denkert, Frederick Klauschen, Jan Budczies, Bruno Valentin Sinn, Denise Treue, U. Keilholz, Helmut Oettle, Hanno Riess, Marianne Sinn, Rosa Schmuck, Sven Bischoff, Frederik Damm
Publikováno v:
Clinical Cancer Research. 26:3732-3739
Purpose: We performed next-generation sequencing (NGS) in the CONKO-001 phase III trial to identify clinically relevant prognostic and predictive mutations and conducted a functional validation in The Cancer Genome Atlas (TCGA) sequencing data. Exper
Autor:
Alex Pearson, Maria Teresa Herrera-Abreu, Alistair Ring, Paula Proszek, E Schuster, Ashutosh Nerurkar, David Gonzalez de Castro, Lina Yuan, Brian A Walker, Ben O'Leary, Javier Pascual, Marina Parton, Mike Hubank, Alicia Okines, Isaac Garcia-Murillas, Stephen R. D. Johnston, Elena Lopez-Knowles, Peter Osin, Mitch Dowsett, Rosalind J. Cutts, Monee K Shamsher, Hannah Bye, Sabri Jamal, Belinda Kingston, Charlotte Fribbens, Nicholas C. Turner
Publikováno v:
Clinical Cancer Research. 26:608-622
Purpose: Advanced breast cancer (ABC) has not been subjected to the same degree of molecular scrutiny as early primary cancer. Breast cancer evolves with time and under the selective pressure of treatment, with the potential to acquire mutations with